ChromaDex (CDXC): Utang-utang marang kapitalisasi buku

The ratio of attracted funds to book capitalization provided by the GURU.Markets system shows that 0.06 represents the latest metric reading for ChromaDex Corporation (CDXC). Current revenues for ChromaDex Corporation (CDXC) are based on the global sales of Tru Niagen, with growth scaling through a partnership with Nestle Health Science to promote Niagen. However, the moderate cyclicality of dietary supplements and inflationary pressure on retail result in average business resilience.
Rincian metrik lan analitis perusahaan chromadex.com (CDXC)

For ChromaDex Corporation (CDXC), which creates unique cellular metabolism components, this indicator assesses the level of financial leverage through the debt-to-market capitalization ratio. The metric determines the business's solvency and default risks based on the current share price. The dynamics of the company's debt relative to its balance sheet capitalization reveal hidden M&A opportunities or an undervaluation of growth. Patent protection for Niagen minimizes operational risks, rendering a low coefficient a sign of high resilience. The stability of this indicator confirms the effectiveness of the strategy to dominate the raw materials market.